Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
boston top stories
15
×
life sciences
national blog main
national top stories
san francisco blog main
san francisco top stories
15
×
new york blog main
new york top stories
san diego blog main
san diego top stories
biotech
national
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
raleigh-durham blog main
raleigh-durham top stories
seattle blog main
seattle top stories
texas top stories
wisconsin blog main
wisconsin top stories
indiana blog main
indiana top stories
texas blog main
clinical trials
fda
boston
cancer
crispr-cas9
drugs
editas medicine
gene editing
merck
akcea therapeutics
alnylam pharmaceuticals
bristol-myers squibb
ceo
What
medicine
15
×
drug
cancer
fda
new
approved
bio
cas
crispr
gene
genetic
known
roundup
alnylam
big
cells
ceo
disease
editas
editing
goes
help
long
making
nobel
patients
precise
prize
published
researchers
risks
study
time
treatment
week
aces
adapt
afternoon
ago
alnylam’s
Language
unset
Current search:
xconomy.com
×
medicine
×
" san francisco top stories "
×
" boston top stories "
×
@xconomy.com
4 years ago
Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks
@xconomy.com
4 years ago
Bio Roundup: Nobel Prizes, Placebo Effect Rises, ICER’s Fire & More
@xconomy.com
4 years ago
Nobel Prize in Medicine Goes to 3 Who Showed How Cells Sense Oxygen Levels
@xconomy.com
4 years ago
As Cholesterol Drug Aces Big Test, MedCo CEO Open to Flexible Pricing
@xconomy.com
4 years ago
Encoded Nabs $104M, Illumina’s Help, to Push Gene Therapy’s Limits
@xconomy.com
5 years ago
Can Tiny Drug Doses (and One Woman’s Fortune) Fight the Most Vicious Cancer?
@xconomy.com
5 years ago
With New Data, Intercept On Track for First-Ever Approved NASH Drug
@xconomy.com
5 years ago
Bio Roundup: Bosley’s Editas Exit, Bridge Bucks, CRISPR Crime & More
@xconomy.com
5 years ago
Bio Roundup: $74B for Celgene, Two CAR-T Tales, Ready for SF & More
@xconomy.com
5 years ago
Genetic Medicine: FDA OKs 2nd Cancer Drug that Targets DNA, not Tissues
@xconomy.com
5 years ago
Alnylam Gets Landmark FDA OK For First-Ever RNAi Drug
@xconomy.com
5 years ago
Patients Have “Fingers Crossed” As Alnylam Awaits Historic FDA Decision
@xconomy.com
5 years ago
CRISPR Risks? Researchers Stoke Fears of Cancer in Gene-Edited Cells
@xconomy.com
6 years ago
Beam Therapeutics Spotlights CRISPR 2.0 with Precise Gene Editor, $87M
@xconomy.com
6 years ago
Will New Study Cut Guesswork for Depression Medicine Prescriptions?